Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.
Tricyclic antidepressants and carbamazepine have become the mainstay in the treatment of neuropathic pain. Within the last decade, controlled trials have shown that numerous other drugs relieve such pain. We identified all placebo-controlled trials and calculated numbers needed to treat (NNT) to obtain one patient with more than 50% pain relief in order to compare the efficacy with the current treatments, and to search for relations between mechanism of pain and drug action. In diabetic neuropathy, NNT was 1.4 in a study with optimal doses of the tricyclic antidepressant imipramine as compared to 2.4 in other studies on tricyclics. The NNT was 6.7 for selective serotonin reuptake inhibitors, 3.3 for carbamazepine, 10.0 for mexiletine, 3.7 for gabapentin, 1.9 for dextromethorphan, 3.4 for tramadol and levodopa and 5.9 for capsaicin. In postherpetic neuralgia, the NNT was 2.3 for tricyclics, 3.2 for gabapentin, 2.5 for oxycodone and 5.3 for capsaicin, whereas dextromethorphan was inactive. In peripheral nerve injury, NNT was 2.5 for tricyclics and 3.5 for capsaicin. In central pain, NNT was 2.5 for tricyclics and 3. 4 for carbamazepine, whereas selective serotonin reuptake inhibitors, mexiletine and dextromethorphan were inactive. There were no clear relations between mechanism of action of the drugs and the effect in distinct pain conditions or for single drug classes and different pain conditions. It is concluded that tricyclic antidepressants in optimal doses appear to be the most efficient treatment of neuropathic pain, but some of the other treatments may be important due to their better tolerability. Relations between drug and pain mechanisms may be elucidated by studies focusing on specific neuropathic pain phenomena such as pain paroxysms and touch-evoked pain.
Sindrup
Søren H
SH
Department of Neurology, Odense University Hospital, DK-5000 Odense C, Denmark Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
Jensen
Troels S
TS
D000700:Analgesics / Q000627:therapeutic use*; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D002220:Carbamazepine / Q000627:therapeutic use; D003929:Diabetic Neuropathies / Q000150:complications*; D006801:Humans; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D009294:Narcotics / Q000627:therapeutic use; D009437:Neuralgia / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D011115:Polyneuropathies / Q000150:complications*; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
D000700:Analgesics; D000929:Antidepressive Agents, Tricyclic; D002220:Carbamazepine; D016202:N-Methylaspartate; D009294:Narcotics; D017367:Selective Serotonin Reuptake Inhibitors